240 related articles for article (PubMed ID: 33399228)
1. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response.
Sweeney KJ; Tetzlaff MT; Vega F; Gillenwater A; Zuo Z; Gross N; Nagarajan P; Wargo J; Nelson K; Prieto VG; Torres-Cabala CA; Curry JL
J Cutan Pathol; 2021 May; 48(5):674-679. PubMed ID: 33399228
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
4. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
7. Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.
Yamakoshi Y; Tanaka H; Sakimura C; Deguchi S; Mori T; Tamura T; Toyokawa T; Muguruma K; Hirakawa K; Ohira M
Int J Oncol; 2020 Jul; 57(1):171-182. PubMed ID: 32319601
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
[TBL] [Abstract][Full Text] [Related]
9. A Case Report of Small Lymphocytic Lymphoma Mimicking Primary Cutaneous Marginal Zone Lymphoma With Plasmacytic Differentiation.
Smith SDB; Aggarwal A; Chen W; Nava VE
Am J Dermatopathol; 2021 Oct; 43(10):730-731. PubMed ID: 33606375
[No Abstract] [Full Text] [Related]
10. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract][Full Text] [Related]
11. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
12. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
13. Tertiary lymphoid structures in tongue cancer: Association with clinicopathological parameters, preoperative S-1 chemotherapy response, and prognosis.
Seki M; Sano T; Saito E; Ogawa M; Yokoo S; Oyama T
J Oral Pathol Med; 2024 Feb; 53(2):124-132. PubMed ID: 38183312
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
15. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
16. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
[TBL] [Abstract][Full Text] [Related]
17. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
18. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
[TBL] [Abstract][Full Text] [Related]
19. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.
Geidel G; Adam L; Rünger A; Menz A; Kött J; Haalck T; Gebhardt C
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1414-e1416. PubMed ID: 37458533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
